Please activate JavaScript!
Please install Adobe Flash Player, click here for download

2012|13 Annual Report Fraunhofer IGB

79 Dipl.-Biol. (t. o.) Ina Hogk Phone +49 711 970-4036 ina.hogk@igb.fraunhofer.de Dr. Anke Burger-Kentischer Phone +49 711 970-4023 anke.burger-kentischer@ igb.fraunhofer.de References [1] Burger-Kentischer, A.; Finkelmeier, D.; Keller, P.; Bauer, J.; Eick- hoff, H.; Kleymann, G. et al. (2011) A screening assay based on host-pathogen interaction models identifies a set of novel anti- fungal benzimidazole derivatives, Antimicrob Agents Chemother 55(10): 4789–4801 [2] Zellbasiertes Testsystem zur Identifizierung und Differen- zierung von Keimspektren (2009) DE 10 2006 031 483 [3] In vitro-Testsystem für virale Infektionen (2012) DE 10 2010 023 156 [4] Hogk, I.; Rupp, S.; Burger-Kentischer, A. (2013) 3D-Tissue model for herpes simplex virus-1 infections. Methods in Molecu- lar Biology, in press Funding We would like to thank the Fraunhofer-Gesellschaft for funding the project “Novel Drug/Gene Delivery Systems for Herpes Simplex Virus (HSV) Therapy”, within the ICON program. Project partner Hebrew University of Jerusalem, Institute for Drug Research (IDR), Jerusalem, Israel The equally patented in-vitro HSV-1 infection model can sub- sequently be used to examine the skin permeability, targeted transport and specific inhibition of viral reactivation by the RNA nano-carriers in a complex test system [3, 4]. Outlook The use of RNAi technology is intended to achieve a target- ed preferably long-term prevention of HSV-1 outbreaks and thereby significantly reduce the suffering of many affected pa- tients. It is likely that this new technology can also be adapted for other virus infections and therefore present great potential in antiviral therapy. 1000mJ/cm2 500mJ/cm2 288mJ/cm2 untreated 5d post UVB72h post UVB 5d post UVB A1 B1 A2 B2 A3 B3 A4 B4 Viral envelope with glycoproteins (gB-gN) Tegument Nucleocapsid 1 TEM image of a cell infected with HSV-1 on a co-culture carrier. 2 Neural cell line (PC12). 3 Cultivation of the HSV-1 infection model. 4 Composition of the co-culture test system. 5 Reactivation of HSV-1 in the co-culture test system. 4 5 Schematic composition and TEM image of HSV-1 Contacts

Pages